Medulloblastoma Clinical Trials
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Recruiting
- High Grade Meningioma
- +4 more
- Bethesda, MarylandNational Cancer Institute (NCI)
2022-04-07
Apr 7, 2022N
Recruiting
- Medulloblastoma
- +4 more
- La Jolla, California
- +9 more
2022-04-07
Apr 7, 2022N
Completed
- Diffuse Intrinsic Pontine Glioma
- +4 more
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022S
Active, not recruiting
- Brain Tumor
- +12 more
- Prexasertib
- +4 more
- Memphis, TennesseeSt. Jude Children's Research Hospital
2022-03-25
Mar 25, 2022S
Recruiting
- Anaplastic Astrocytoma
- +55 more
- Gemcitabine
- +4 more
- Memphis, TennesseeSt. Jude Children's Research Hospital
2022-04-01
Apr 1, 2022T
Recruiting
- Ependymoma
- +3 more
- Ibrutinib
- +3 more
- Augusta, GeorgiaAugusta University, Georgia Cancer Center
2022-03-20
Mar 20, 2022T
C
C
Recruiting
- Ependymoma
- +3 more
- IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes
- Duarte, CaliforniaCity of Hope Medical Center
2022-03-09
Mar 9, 2022G
No longer available
- Neuroblastoma
- +5 more
- eflornithine HCl
- Charlotte, North CarolinaLevine Children's Hospital
2022-03-03
Mar 3, 2022R
Not yet recruiting
- High Grade Glioma
- +12 more
- LUTATHERA® (Lutetium Lu 177 dotatate)
- Aurora, Colorado
- +8 more
2022-03-03
Mar 3, 2022S
Recruiting
- Brain Tumor
- Medulloblastoma
- Memphis, TennesseeSt.Jude Children's Research Hospital
2022-03-07
Mar 7, 2022P
Active, not recruiting
- Medulloblastoma
- +7 more
- SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years
- +2 more
- Buffalo, New YorkRoswell Park Comprehensive Cancer Center
2022-02-15
Feb 15, 2022C
Recruiting
- Central Nervous System Neoplasms
- +22 more
- Bethesda, MarylandNational Institutes of Health
2022-03-01
Mar 1, 2022S
Recruiting
- Central Nervous System Tumor, Pediatric
- +8 more
- HER2-specific chimeric antigen receptor (CAR) T cell
- Seattle, WashingtonSeattle Children's Hospital
2022-02-10
Feb 10, 2022U
Terminated
- Lymphoma
- +15 more
- Genistein
- Placebo
- Charlottesville, VirginiaUniversity of Virginia
2022-02-08
Feb 8, 2022U
Recruiting
- Medulloblastoma
- +2 more
- Specialized Tumor Board Treatment Plan
- San Diego, California
- +2 more
2022-02-22
Feb 22, 2022G
Active, not recruiting
- Neuroblastoma
- +3 more
- Guided Therapy- Pediatric Gene Analysis Platform
- Phoenix, Arizona
- +12 more
2022-02-16
Feb 16, 2022G
Active, not recruiting
- Neuroblastoma
- +18 more
- Guided Therapy
- Little Rock, Arkansas
- +18 more
2022-02-16
Feb 16, 2022G
Active, not recruiting
- Neuroblastoma
- Medulloblastoma
- Nifurtimox
- +2 more
- San Diego, California
- +14 more
2022-02-16
Feb 16, 2022N
Recruiting
- Medulloblastoma
- Central Nervous System Embryonal Tumors
- Induction
- +2 more
- Birmingham, Alabama
- +61 more
2022-02-16
Feb 16, 2022S
Recruiting
- Central Nervous System Tumor, Pediatric
- +8 more
- EGFR806-specific chimeric antigen receptor (CAR) T cell
- Seattle, WashingtonSeattle Children's Hospital
2022-02-09
Feb 9, 2022U
Active, not recruiting
- Medulloblastoma
- Neuroectodermal Tumor
- TTRNA-xALT
- TTRNA-DCs
- Los Angeles, California
- +2 more
2022-01-07
Jan 7, 2022B
Recruiting
- Neuroendocrine Tumors
- +15 more
- 68Ga-DOTATOC PET/CT
- 18F-FDG PET/CT
- Vancouver, British Columbia, CanadaBC Cancer
2022-02-02
Feb 2, 2022C
Active, not recruiting
- Desmoplastic/Nodular Medulloblastoma
- +4 more
- Carboplatin
- +6 more
- Birmingham, Alabama
- +172 more
2022-01-04
Jan 4, 2022